Qiagen N.v. · NYSE:QGEN
Qiagen — J.P. Morgan Healthcare Conference 2022
17 slides from Qiagen's conference presentation, Jan 10, 2022
Slide 1: Emerging from change with a strengthened profile
Sample to Insight Emerging from change with a strengthened profile J.P. Morgan Healthcare Conference January 2022 Thierry Bernard Chief Executive Officer
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S.
Slide 3: Our Mission and Vision
Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible January 10, 2022 J.P. Morgan Healthcare Conference 3
Slide 4: QIAGEN at a glance
QIAGEN at a glance Strong 2021 sales performance Balanced customer base >500,000 customers >$2 bn ~50% ~50% worldwide Molecular Life Sciences Diagnostics Diverse global presence Highly recurring revenues Americas ~20% ~45% ~88% ~12% EMEA Sales Consumables Instruments and related revenues Asia-Pacifi
Slide 5: Key messages
Key messages Determined leadership team delivering on commitments and developing EMPOWER culture Focusing on driving growth in non-COVID product groups while fully supporting volatile COVID-19 testing trends Compelling investment case combining highly recurring revenues, broad customer base and geog
Slide 6: Emerging stronger from a time of change
Emerging stronger from a time of change Resetting the business COVID-relevant, but not COVID-dependent Capturing new opportunities • Leadership changes • Focused on 5 pillars of growth strategy • Rebalance non-COVID vs COVID sales • Strategic review • Answered dynamic pandemic demand • Further devel
Slide 7: Addressing COVID-19 testing from a pandemic to an endemic
Addressing COVID-19 testing from a pandemic to an endemic TESTING SURVEILLANCE RNA sample preparation Immune testing • QIAprep& • QuantiFERON SARS-CoV-2 T cell test • Viral RNA purification • QIAreach Anti-SARS-CoV-2 Total antibody test PCR testing solutions NGS variant monitoring • QIAstat-Dx •
Slide 8: Delivering on our promises: 2021 accomplishments
Delivering on our promises: 2021 accomplishments Empowered teams achieved our goals Sample technologies • QIApre&Amp for high-throughput COVID testing • 2021 9M: +25% CER sales growth, Adj EPS $1.88 CER, • EZ2 Connect instruments free cash flow $302 million • Set ambitious but realistic targets: Met
Slide 9: Macro trends fueling attractive opportunities in 2022 and beyond
Macro trends fueling attractive opportunities in 2022 and beyond 2022 budget Routine testing vs increases over PY pre-pandemic level Research funding United United Regular clinical December December increasing States Kingdom testing returns to 2020 2021 +12-15% +15% growth -4% +11% (proposed) Resear
Slide 10: Advancing our five pillars of growth
Advancing our five pillars of growth Targeting >$6 billion of our >$11 billion total addressable market Expanding on solid leadership Early commercialization phases with strong growth potential Sample technologies QuantiFERON QIAstat-Dx NeuMoDx QIAcuity • Leading reputation, • Fully automated • Samp
Slide 11: Building on Sample Technologies solid leadership
Building on Sample Technologies solid leadership Upgrading key automation platforms Comprehensive consumables portfolio QIAcube Connect EZ2 Connect QIAsymphony Boost Launched 2019 Launched 2021 In development Over 300 kits • Any sample format Add photo • Any analyte for QS (DNA, RNA, Proteins) boost
Slide 12: Leveraging novel technology with QIAcuity digital PCR
Leveraging novel technology with QIAcuity digital PCR QIAcuity dPCR: Accessing the comprehensive PCR market Complete portfolio for research use QIAcuity New partnerships expanding breadth of applications NEW Accuracy Non-Invasive Proteomics testing Prenatal testing QIAcuity One QIAcuity Four QIAcuit
Slide 13: Capturing opportunities with QIAstat-Dx syndromic testing
Capturing opportunities with QIAstat-Dx syndromic testing Broadening the addressable market with QIAstat-Dx Rise Growing test menu CE-IVD FDA Gastrointestinal Small hospitals Medium-sized hospitals National reference labs, Public health labs Regional reference labs Large IDNs Respiratory Single test
Slide 14: Expanding QuantiFERON leadership to access untapped markets
Expanding QuantiFERON leadership to access untapped markets QIAreach-QuantiFERON TB NEW QuantiFERON-Lyme Decentralized screening solution for high-burden, low-resource areas Addressing growing opportunity for early detection of Lyme Disease Lyme Disease in western Europe ~$400-600 Estimated cases(1)
Slide 15: Supporting growth while increasing returns to shareholders
Supporting growth while increasing returns to shareholders Healthy cash flow and leverage ratio trends Invest in the business $ millions Fuel sustainable and profitable growth, 500 1.5x 1.8 especially in the five pillars 1.6x 1.1x 1.5x 1.6 1.4x 400 1.4 458 1.2 Enhance value with M&A 300 1.0 359 331
Slide 16: Strong de-risked investment case with compelling differentiation
Strong de-risked investment case with compelling differentiation Highly recurring Broad geographic Diversified revenues reach customer base Sales driven by steady customer Robust structures securing access to Well-balanced sales split between shipments of high margin consumables markets across the g
Slide 17: Summary
Summary Determined leadership team delivering on commitments and developing EMPOWER culture Focusing on driving growth in non-COVID product groups while fully supporting volatile COVID-19 testing trends Compelling investment case combining highly recurring revenues, broad customer base and geographi